Back to Hematology
Hematologyv2005Evidence-Based

Multiple Myeloma International Staging System (ISS)

Prognosticates severity of multiple myeloma based on routinely obtained lab values including serum β2 microglobulin and albumin levels.

Clinical Input Parameters

mg/L
Range: 0.1 — 50 mg/L
g/dL
Range: 1 — 6 g/dL
Clinical Assessment
Awaiting Parameters
iss stage
—Points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Multiple Myeloma International Staging System (ISS) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

ISS Stage determination: Stage I = β2 microglobulin <3.5 mg/L AND albumin ≥3.5 g/dL; Stage II = (β2 microglobulin <3.5 mg/L AND albumin <3.5 g/dL) OR (β2 microglobulin 3.5-5.4 mg/L); Stage III = β2 microglobulin ≥5.5 mg/L

Clinical Pearls & Practice Notes

  • Developed from database of 10,750 multiple myeloma patients from 1981-2002
  • Uses only two easily obtainable laboratory parameters
  • Simpler and more objective than previous Durie-Salmon staging system
  • Validated across multiple international patient populations
  • Should only be used for newly diagnosed multiple myeloma patients
  • Not validated for relapsed myeloma, smoldering myeloma, or MGUS
  • β2 microglobulin reflects tumor burden and kidney function
  • Albumin reflects nutritional status and disease burden
  • Higher β2 microglobulin levels correlate with worse prognosis
  • Lower albumin levels correlate with worse prognosis
  • Stage I has the best median overall survival (62 months)
  • Stage II has intermediate median overall survival (44 months)
  • Stage III has the poorest median overall survival (29 months)
  • ISS staging should be performed at diagnosis for all patients
  • Results help guide treatment intensity and prognosis counseling
  • Often used in conjunction with cytogenetic risk assessment
  • The Revised ISS (R-ISS) incorporates additional genetic factors
  • ISS remains widely used due to simplicity and availability of parameters
  • Should be interpreted alongside other prognostic factors
  • Regular reassessment during treatment may provide additional prognostic information

Evidence & Literature Citations

  1. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20. doi: 10.1200/JCO.2005.04.242.
  2. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u.
  3. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267.

Score Interpretation Ranges

Stage I1 – 1 pts

Best prognosis

Stage II2 – 2 pts

Intermediate prognosis

Stage III3 – 3 pts

Poorest prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.